Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Hervé Dombret, Emmanuel Raffoux et al.|The Lancet Haematology|2016Cited by 431
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionNathalie Jacque, Didier Bouscary, Anne Marie Ronchetti et al.|Blood|2015Cited by 383
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaÉric Jourdan, Hervé Dombret, Éric Delabesse et al.|Blood|2013Cited by 357
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Marie Sébert, Laëtitia Largeaud et al.|Blood|2022Cited by 80
Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemiaClément Larrue, Christian Récher|Oncogenesis|2019Cited by 43